Tavapadon, sold under the brand name JUVMO, won FDA approval on September 28, 2026 for adults with Parkinson’s disease, and its maker AbbVie describes it as the first and only selective D1/D5 receptor agonist cleared for the condition. The tablet is taken once a day, and the company expects it to reach U.S. pharmacies in October 2026, which is this month. The first-in-class wording originates with AbbVie; the approval itself is a separate regulatory fact, and the two deserve to be read apart.
Behind the label sits a three-part Phase 3 program called TEMPO, covering patients who had not yet started levodopa and patients already struggling with it. Tablets come in 5 mg, 10 mg and 15 mg strengths, and a titration pack adds 0.25 mg and 1 mg tablets so that doctors can raise the dose in steps rather than all at once.
D1/D5 Receptors Versus the D2/D3 Agonists Already Sold
AbbVie’s announcement says JUVMO is “the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease,” a sentence the company’s own press release carries in its first paragraphs. Roopal Thakkar, AbbVie’s executive vice president for research and development and chief scientific officer, went further in the same document, calling the approval “the first dopaminergic breakthrough for Parkinson’s disease in decades.” Both statements are the company’s characterization, offered on the day of approval, and neither comes from the FDA.
The mechanism is the substance behind the slogan. Trade coverage in Drug Topics notes that existing dopamine agonists act mainly on D2 and D3 receptors, while tavapadon is built to hit D1 and D5 receptors selectively. The pitch is a different route to the same dopamine pathway, aimed at easing motor symptoms and reducing how much levodopa patients need over time.
The disease it targets is common. The Parkinson’s Foundation estimates that 1.1 million people in the United States live with Parkinson’s and that nearly 90,000 are diagnosed each year. The National Institute of Neurological Disorders and Stroke explains that by the time symptoms appear, most people have lost 60 to 80 percent or more of the dopamine-producing cells in the substantia nigra, and that levodopa’s benefit fades into sudden, unpredictable “off” periods as the illness advances.
TEMPO-3 and the 1.7-Hour Gain
The leading efficacy number comes from TEMPO-3, the trial in patients on levodopa who had motor fluctuations. According to AbbVie, “on” time without troublesome dyskinesia rose by 1.7 hours with JUVMO against 0.6 hours with placebo, a gap with a p-value under 0.0001, and “off” time fell by 1.9 hours against 0.9 hours. Practical Neurology reports the same 1.7 and 0.6 hours; the net advantage over placebo is therefore about 1.1 hours a day, a figure other outlets quote instead. The distinction matters when reading coverage, because 1.7 hours is the absolute change on the drug and 1.1 hours is the drug-minus-placebo difference. Both describe the same trial result, and neither should be read as an extra hour and a half of symptom-free time on top of existing treatment for every patient.
Hubert Fernandez, M.D., of the Cleveland Clinic, a principal investigator on TEMPO, described the drug in AbbVie’s release as a novel therapy that selectively targets D1/D5 receptors and addresses a longstanding need for innovation. The early-disease trials, TEMPO-1 and TEMPO-2, tested tavapadon in people not yet on levodopa; Practical Neurology summarizes symptom-scale gains of 9.7 to 10.2 points against a 1.8-point worsening on placebo. In the open-label extension, TEMPO-4, AbbVie reports that at 85 weeks 93 percent of patients on JUVMO had not increased their levodopa dose, and 94 percent who started without levodopa had never begun it.
Label Warnings: Blood Pressure, Urges and Hallucinations
Safety language in AbbVie’s release lists nausea, headache, taste change, fatigue, vomiting, dry mouth, anxiety, dizziness, orthostatic hypotension, hallucinations and dyskinesia as common side effects. The serious concerns it flags are low blood pressure, unusual urges such as gambling or compulsive eating and shopping, hallucinations and involuntary movements.
Drug Topics adds numbers from TEMPO-3: adverse events occurred in 71.7 percent of tavapadon patients versus 55.1 percent on placebo, and impulse-control signals appeared in six tavapadon-treated participants against three on placebo. Brian Fiske, Ph.D., chief scientist at the Michael J. Fox Foundation, is quoted in AbbVie’s materials saying “progress means having treatment options that deliver meaningful benefit in everyday life,” a framing that leaves the weighing of benefit and risk to prescribers.
The Approval Record Versus the Company Claim
Several trade outlets echo the first-in-class status, with HMP Global’s neurology site calling it the first selective D1/D5 receptor agonist approval for this indication. That repetition traces back to AbbVie, since Practical Neurology’s account of the same approval does not itself state the first-in-class point. No FDA document confirming the designation could be read, so the “first” stays attributed to the company rather than to the agency.
What can be pinned down is the date and the supply plan: approval on September 28, 2026, a once-daily tablet in three strengths plus titration tablets, and U.S. availability that AbbVie puts in October 2026.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Card skimmers hidden on gas pumps and ATMs are draining accounts, and here’s the tell
- Hurricane Hunter radar shows four warning signs that a tropical cyclone is about to strengthen, a University of Miami study found
- NTSB report details how a family of four died when their plane’s nose suddenly pitched up
- Doctors warn a silent liver disease now affects one in three American adults
